The Board of Pharmacy adopted the following permanent rules.
| Permanent Rule | Effective Date |
| Division 007/041/045/065 – related to USP, Labeling, Repackaging | December 16, 2021 |
| Division 010 – related to Board Administration & Policies | December 16, 2021 |
| Division 019/021 – related to Pain Management CE | January 1, 2022 |
| Division 019/139 – related to Remote Dispensing Site Pharmacy/Telepharmacy | January 1, 2022 |
| Division 041 – related to Telework | December 16, 2021 |
| Division 041 – related to TCVP (Technician Checking Validation Program) | October 1, 2022 |
| Division 041/080 – related to Pseudoephedrine/Ephedrine | January 1, 2022 |
| Division 043 – related to SPDO/DPDO/CHC | January 1, 2022 |
| Division 043 – related to SPDO (Supervising Physician Dispensing Outlet) | March 31, 2022 |
| Division 060/110 – related to PDMP Fee Increase | January 1, 2022 |
Also in Oregon, as a reminder, effective January 1, 2022, drugs containing pseudoephedrine and ephedrine may be purchase without a prescription. See item above regarding the permanent rule related to pseudoephedrine/ephedrine. For information about the use of the National Precursor Log Exchange (NPLEx) system, please refer to the Board of Pharmacy’s November 2021 newsletter.
Also in Oregon, the Board of Pharmacy issued a notice requesting fiscal impact estimates from stakeholders for temporary and permanent pharmacy closures. Note: any information provided to the Board becomes a public record.
Finally in Oregon, the Board of Pharmacy’s CE Rules Advisory Committee will meet on January 18. Details to participate in the meeting via phone conference are available in the agenda.
For more information, contact NACDS’ Sandra Guckian at 703-774-4801.